MXCT vs TPR · rev $38.6M vs P/E 46, rev $8.00B
MaxCyte Inc (MXCT) versus Tapestry Inc (TPR) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Tapestry Inc (TPR) is a luxury goods company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported TPR revenue for 2026-06-27 was $8.00B. Net income was $1.53B. Revenue was up 14.2% from 2025-06-28 to 2026-06-27. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
MXCT currently screens at market cap $124.3M. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
Not investment advice. Open the MXCT and TPR stock pages for the full models.
Not investment advice.